These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. Parra ER; Villalobos P; Behrens C; Jiang M; Pataer A; Swisher SG; William WN; Zhang J; Lee J; Cascone T; Heymach JV; Forget MA; Haymaker C; Bernatchez C; Kalhor N; Weissferdt A; Moran C; Zhang J; Vaporciyan A; Gibbons DL; Sepesi B; Wistuba II J Immunother Cancer; 2018 Jun; 6(1):48. PubMed ID: 29871672 [TBL] [Abstract][Full Text] [Related]
3. Optimizing the spatial immune landscape of CD103 Yang G; Hu M; Cai S; Li C; Yang L; Zhao M; Jing H; Xing L; Sun X Cell Oncol (Dordr); 2024 Oct; 47(5):1957-1971. PubMed ID: 39158668 [TBL] [Abstract][Full Text] [Related]
4. PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127 Hui Z; Ren Y; Zhang D; Chen Y; Yu W; Cao J; Liu L; Wang T; Xiao S; Zheng L; Pu Y; Wei F; You J; Ren X NPJ Precis Oncol; 2023 May; 7(1):48. PubMed ID: 37231145 [TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant immunochemotherapy improves clinical outcomes of patients with esophageal cancer by mediating anti-tumor immunity of CD8+ T (Tc1) and CD16+ NK cells. He Y; Yang D; Lin X; Zhang J; Cheng R; Cao L; Yang L; Zhang M; Shi X; Jin X; Sun H; Sun H; Zang J; Li Y; Ma J; Nie H Front Immunol; 2024; 15():1412693. PubMed ID: 39076970 [TBL] [Abstract][Full Text] [Related]
6. T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC. Yi L; Xu Z; Ma T; Wang C; Wei P; Xiao B; Zhang H; Che N; Liu Z; Han Y Cancer Immunol Immunother; 2024 Apr; 73(6):99. PubMed ID: 38619623 [TBL] [Abstract][Full Text] [Related]
7. The Emerging Role of CD8 Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F Front Immunol; 2018; 9():1904. PubMed ID: 30158938 [TBL] [Abstract][Full Text] [Related]
8. Functional Heterogeneity of CD4 Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P Front Immunol; 2018; 9():2654. PubMed ID: 30505306 [TBL] [Abstract][Full Text] [Related]
9. Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma. Arbore G; Albarello L; Bucci G; Punta M; Cossu A; Fanti L; Maurizio A; Di Mauro F; Bilello V; Arrigoni G; Bonfiglio S; Biancolini D; Puccetti F; Elmore U; Vago L; Cascinu S; Tonon G; Rosati R; Casorati G; Dellabona P Cancer Res; 2023 Sep; 83(17):2873-2888. PubMed ID: 37350667 [TBL] [Abstract][Full Text] [Related]
10. Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients. Cole KE; Ly QP; Hollingsworth MA; Cox JL; Fisher KW; Padussis JC; Foster JM; Vargas LM; Talmadge JE Int Immunopharmacol; 2022 May; 106():108628. PubMed ID: 35203041 [TBL] [Abstract][Full Text] [Related]
11. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008 [TBL] [Abstract][Full Text] [Related]
12. Single-cell transcriptomics reveals tumor-infiltrating B cell function after neoadjuvant pembrolizumab and chemotherapy in non-small cell lung cancer. Hou L; Zhang S; Yu W; Yang X; Shen M; Hao X; Ren X; Sun Q J Leukoc Biol; 2024 Sep; 116(3):555-564. PubMed ID: 37931147 [TBL] [Abstract][Full Text] [Related]
13. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. Djenidi F; Adam J; Goubar A; Durgeau A; Meurice G; de Montpréville V; Validire P; Besse B; Mami-Chouaib F J Immunol; 2015 Apr; 194(7):3475-86. PubMed ID: 25725111 [TBL] [Abstract][Full Text] [Related]
14. Location of CD39 Koppensteiner L; Mathieson L; Pattle S; Dorward DA; O'Connor R; Akram AR J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37648263 [TBL] [Abstract][Full Text] [Related]
15. Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. Hu J; Zhang L; Xia H; Yan Y; Zhu X; Sun F; Sun L; Li S; Li D; Wang J; Han Y; Zhang J; Bian D; Yu H; Chen Y; Fan P; Ma Q; Jiang G; Wang C; Zhang P Genome Med; 2023 Mar; 15(1):14. PubMed ID: 36869384 [TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant PD-1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung. Feng Y; Sun W; Zhang J; Wang Y; Chen J; Liu X; Wang L; Li S; Lv C; Lu F; Zhang J; Hong Y; Xiao S; Wang T; Jiao R; Wang Z; Qi L; Li N; Yang Y; Lin D; Fang J Thorac Cancer; 2022 Feb; 13(3):442-452. PubMed ID: 34913597 [TBL] [Abstract][Full Text] [Related]
17. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner. Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370 [TBL] [Abstract][Full Text] [Related]
18. Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis. Xing X; Shi J; Jia Y; Dou Y; Li Z; Dong B; Guo T; Cheng X; Li X; Du H; Hu Y; Jia S; Zhang J; Li Z; Ji J J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35361730 [TBL] [Abstract][Full Text] [Related]
19. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation. Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304 [TBL] [Abstract][Full Text] [Related]
20. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer. Mori T; Tanaka H; Suzuki S; Deguchi S; Yamakoshi Y; Yoshii M; Miki Y; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M Cancer Sci; 2021 May; 112(5):1746-1757. PubMed ID: 33735485 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]